Literature DB >> 11578368

DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary.

J. Kaern1, C.G. Tropé, G.B. Kristensen, V.M. Abeler, E.O. Pettersen.   

Abstract

The prognostic significance of DNA ploidy in relation to clinical and histopathologic factors was evaluated in a retrospective study of 370 patients treated at the Norwegian Radium Hospital from 1970 to 1982 with complete follow-up of median 149 months. Evaluable flow cytometric DNA histograms from paraffin-embedded tissue from the primary tumor were obtained in 321 cases, 293 (91%) were diploid and 28 (9%) were aneuploid. Aneuploidy was associated with older age, more advanced disease and non-serous histologic types. By multivariate analysis the only parameters with prognostic significance for corrected survival (death from disease) were ploidy, stage, histologic type and age. The patients with aneuploid tumors had a 19-fold increased risk of dying of disease compared with patients with diploid tumors. In tumor-free operated patients the extent of surgery had no influence on survival, neither had postoperative treatment. Using the prognostic factors the patients could be divided into risk groups. The large group of patients with diploid stage I tumors belonged to the low risk group. Fertility-saving operations can be offered to patients with diploid stage IA tumors, all others should have bilateral salpingo-oophorectomy and omentectomy with or without hysterectomy. Patients with diploid stage I tumors should not receive adjuvant treatment. The value of adjuvant chemotherapy in the high risk group needs further investigation.

Entities:  

Year:  1993        PMID: 11578368     DOI: 10.1046/j.1525-1438.1993.03060349.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  8 in total

1.  Error-promoting DNA synthesis in ovarian cancer cells.

Authors:  Heqiao Dai; Robert J Hickey; Jianying Liu; Robert M Bigsby; Carita Lanner; Linda H Malkas
Journal:  Gynecol Oncol       Date:  2013-07-12       Impact factor: 5.482

2.  TFF3 Expression as Stratification Marker in Borderline Epithelial Tumors of the Ovary.

Authors:  Ahmed El-Balat; Iryna Schmeil; Thomas Karn; Sven Becker; Nicole Sänger; Uwe Holtrich; Ruza Arsenic
Journal:  Pathol Oncol Res       Date:  2017-05-03       Impact factor: 3.201

3.  Risk factors for recurrence of ovarian borderline tumors.

Authors:  K K Shih; Q Zhou; J Huh; J C Morgan; A Iasonos; C Aghajanian; D S Chi; R R Barakat; N R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2010-12-10       Impact factor: 5.482

4.  Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors.

Authors:  Karin K Shih; Qin C Zhou; Carol Aghajanian; Jae Huh; Robert A Soslow; Jessica C Morgan; Alexia Iasonos; Dennis S Chi; Richard R Barakat; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2010-08-16       Impact factor: 5.482

Review 5.  Revisiting tumour aneuploidy - the place of ploidy assessment in the molecular era.

Authors:  Håvard E Danielsen; Manohar Pradhan; Marco Novelli
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

6.  Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications.

Authors:  Manohar Pradhan; Ben Davidson; Claes Göran Tropé; Håvard Emil Danielsen; Vera Maria Abeler; Björn Risberg
Journal:  Virchows Arch       Date:  2009-05-08       Impact factor: 4.064

7.  Serous borderline tumor of the fallopian tube presented as hematosalpinx: a case report.

Authors:  Maja Krasevic; Teodora Stankovic; Oleg Petrovic; Neda Smiljan-Severinski
Journal:  BMC Cancer       Date:  2005-10-07       Impact factor: 4.430

8.  Age-dependent difference in impact of fertility preserving surgery on disease-specific survival in women with stage I borderline ovarian tumors.

Authors:  Haiyan Sun; Xi Chen; Tao Zhu; Nanfang Liu; Aijun Yu; Shihua Wang
Journal:  J Ovarian Res       Date:  2018-06-29       Impact factor: 4.234

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.